Vermont Pharmacists Association
P.O. Box 90, Woodstock, VT 05091

877.483.2646

P.O. Box 90, Woodstock, VT 05091

877.483.2646

Stacks Image p1166_n1160
RRMM REGIONAL MEETING ADAPTATION
I'm an educational project manager with MediCom Worldwide, a medical education company responsible for several online communities including www.ManagingMyeloma.com. We have a complimentary activity that has been adapted from our live meeting series held in September called "When First-Line Treatment Fails: Navigating New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma," accredited by the MD Anderson Cancer Center at the University of Texas. 




When First-Line Treatment Fails: Navigating New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma
CME, CPE, CNE
Andrzej Jakubowiak, MD, PhD and Philip L. McCarthy, MD

Release Date: November 21, 2016
Expiration Date: November 21, 2017
The treatment of multiple myeloma (MM) has changed dramatically in the past several years, with numerous innovations resulting in significant improvement in outcomes and long-term survival for many patients. Despite the new advances, however, significant challenges remain, particularly in patients with relapsed/refractory multiple myeloma (RRMM). To support an increased understanding of new therapeutic choices in the treatment of RRMM and to provide practical education that delivers up-to-date information, expert faculty will share their latest insights and experiences. During this activity, recorded from a live meeting in Chicago in September 2016, we will discuss recent advances in the treatment of relapsed/refractory disease and how to navigate among the current agents to find the right treatment option for your patients. This program will describe new agents used in practice today, review current guidelines, share best practices, and review patient-centered treatment strategies in RRMM.
Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Bristol-Myers Squibb Company and Takeda Oncology.

BEGIN







ACPE Pharmacy CE through the Ohio Pharmacists Foundation

The Ohio Pharmacists Foundation will provide the ACPE credit for all quizzes.  The CE user will pay $5 per article to the Ohio Pharmacists Association (OPA) for grading, recordkeeping, and statement of CE credit.  Payment and quiz sheet are to be returned to OPA at the location listed on the quiz sheet.  Statements of CE credit will be mailed to successful participants six times a year: February, April, June, August, October and December.

Articles and quizzes are available through the links below in pdf format. You may download them to your computer and print them out.

New Drugs: Dalvance, Entyvio, Jublia, and Zontivity
To receive CE credit, your quiz must be received no later than March 15, 2018.

Heart Failure: Updated Treatment Guidelines
To receive CE credit, your quiz must be received no later than February 15, 2018.

New Drugs: Cyramza, Sylvant, Tanzeum, and Zykadia
To receive CE credit, your quiz must be received no later than January 15, 2018




To receive CE credit, your quiz must be received no later than April 15, 2018.
To receive CE credit, your quiz must be received no later than February 15, 2019.
To receive CE credit, your quiz must be received no later than December 15, 2019.
To receive CE credit, your quiz must be received no later than February 15, 2020.
To receive CE credit, your quiz must be received no later than March 15, 2020.
To receive CE credit, your quiz must be received no later than August 15, 2020.
To receive CE credit, your quiz must be received no later than September 15, 2020.